Precigen (PGEN) Stock Analysis & AI Equity Report
Precigen (PGEN) overview
Precigen (PGEN) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 9.7m and operating profit of USD -111m; the year-end share price was 4.18 USD and market capitalisation was USD 1,479m. Precigen is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Precigen's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About Precigen
Precigen is a commercial-stage biopharmaceutical company developing precision medicines for immuno-oncology, autoimmune disorders, and infectious diseases. Its approved product, Papzimeos, is an immunotherapy for adults with recurrent respiratory papillomatosis. The company’s platforms include AdenoVerse immunotherapy and UltraCAR-T, and its pipeline includes clinical-stage candidates for cancer. It also developed the UltraPorator device to support manufacturing of UltraCAR-T therapies.
Generate the Precigen report
Precigen is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Precigen and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on Precigen
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.